United Financial Group

Investing with us,
you create the future

“Someone is sitting in the shade today because
someone planted a tree a long time ago“ - Warren Buffett

About company

  • United Financial Group
  • Own developments in the biotechnology field
  • Launching safe broad-spectrum medicinal products on the market
  • Funding for promising medical developments and scientists
  • Participation and financing of IT and Blockchain developments

The year of foundation of the Company


Launch of the first product on the market


Payment of the first dividends


Countries of the project participants


Company's mission:

  • Development and market launch of safe drugs for the treatment of oncology
  • Launch of new broad-spectrum drugs on the market
  • Financing of IT-areas
  • Financing of scientists and promising developments
  • Creating a balanced investment portfolio for investors



Investments in a promising business with a turnover of more than $ 200 billion dollars a year


An opportunity to have access to all preparations and company developments at the lowest prices


The annual payment of dividends to investors of the company, after calculating the annual profit


The ability to transfer their shares in the company by inheritance


Participation in the creation of an important area in the safe therapy and treatment of many diseases


Profit from all development and investment tools of the company


Why is it profitable to invest in new
technologies and developments?


in 2010, the company's share was worth $ 0.009, and after 9 years the price rose to $ 44 per share. An investment of $ 100 in Uber, after 9 years made a profit of $ 500,000


The company was founded in 1996. Initial investment in the company amounted to $ 25 million. The current capitalization of the company is about 1 trillion dollars. An investment of $ 100 in 1998 grew to $ 4,000,000 after 20 years.


Steve Jobs, Steve Wozniak, and Ron Wayne founded the company in 1976. Ron Wayne sold his 10% stake for $ 800 in 2 weeks. Today 10% of the company costs about $ 100 billion!


The company was founded in 1999. Attracted investments of $ 25,000,000. At the beginning of 2020, market capitalization exceeded $ 600 billion. $ 100 of investments grew to $ 2.4 million

Today, all these companies are popular and
famous, but few years ago few believed that
they had a future, for this very reason,
the shares of these companies were cheap.

Investment directions

Medical direction:

Finished Products:

In developing:

  • AstroMelanin is a broad-spectrum drug (more)

IT direction:

Finished Products:

  • Cooperation and investment in Yllo Blockchain One company.
    Blockchain technology company combines several products based on its own core. (more)

Market volume

Demand for drug development

Pfizer Acquires Campto for $ 620 Million

Sanofi-Synthelabo announced that it has signed an agreement with Pfizer Inc. regarding the divestment of Aventis’ interests in Campto (irinotecan) in response to requests made by the competition authorities.Subject to the success of Sanofi-Synthelabo’s offer for Aventis, Pfizer will take over clinical studies for Campto that are currently conducted by Aventis, together with certain patents and other assets pertaining to territories where Pfizer currently markets irinotecan. The consideration for the whole transaction is of $620 million.


Read moreHidde

GSK reaches an agreement to acquire TESARO, a biopharmaceutical oncology company

GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion). The proposed transaction will significantly strengthen GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology.

Read moreHidde

Pfizer buys cancer drug maker Array BioPharma

NEW YORK & BOULDER, Colo.--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Array BioPharma Inc. (NASDAQ: ARRY) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. Pfizer has agreed to acquire Array for $48 per share in cash, for a total enterprise value of approximately $11.4 billion. The Boards of Directors of both companies have approved the merger.


Read moreHidde

Pfizer Offers $ 14 Billion For Medivation Oncology Manufacturer

Pfizer Inc. (NYSE:PFE) and Medivation, Inc. (NASDAQ:MDVN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion.

Read moreHidde
Company Rx Sales
R&D spend
$45.302 $7.962
$44.552 $9.803
$43.481 $8.154
Johnson & Johnson
$38.815 $8.446
Merck & Co.
$37.353 $7.908
$35.121 $6.227
$32.067 $5.093
$30.645 $4.987
$22.533 $3.657
Gilead Science
$21.677 $3.897